Peter C. Everett, MD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MD, Boston University School of Medicine
BS, Cornell University



Dr. Peter Everett is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the Section of Hematology and Medical Oncology at Boston Medical Center (BMC). He received his undergraduate degree from Cornell University and his medical degree from Chobanian and Avedisian School of Medicine. Following that, he completed training in Internal Medicine and a fellowship in Hematology and Medical Oncology at Boston Medical Center, where he also served as the Chief Fellow. Dr. Everett specializes in head, neck and thoracic oncology.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research





RTOG 3521: TRANSPARENT: Single Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
09/03/2024 - 09/02/2027 (Subcontract PI)
PI: Peter C. Everett, MD
Radiation Therapy Oncology Group Coherus BioSciences

LEAP-009: A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participa
09/14/2022 - 09/13/2025 (PI)
Merck

17-411
04/04/2019 - 04/04/2022 (PI)
Dana Farber Cancer Institute

17-411
04/04/2019 - 04/04/2022 (PI)
Dana Farber

MK-3475-671-00
02/22/2019 - 02/22/2022 (PI)
Merck

MK-3475-671-00
02/22/2019 - 02/22/2022 (PI)
Merck

Merck 598-A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs…
06/01/2018 - 05/31/2021 (PI)
Merck


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789.View Related Profiles. PMID: 37288789
     
  2. Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893.View Related Profiles. PMID: 36071763; PMCID: PMC9442513; DOI: 10.21037/jtd-22-210;
     
  3. Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. PMID: 34667025; PMCID: PMC9401515; DOI: 10.1158/1078-0432.CCR-21-2635;
     
  4. Freydman J, Henshaw L, Patel JV, Smith CE, Everett PC. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. Ann Pharmacother. 2022 04; 56(4):503-504. PMID: 34344199
     
  5. Tapan U, Furtado VF, Qureshi MM, Everett P, Suzuki K, Mak KS. Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC. JTO Clin Res Rep. 2021 Jan; 2(1):100109.View Related Profiles. PMID: 34589974; PMCID: PMC8474393; DOI: 10.1016/j.jtocrr.2020.100109;
     
  6. Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 10; 129(10):2313-2320.View Related Profiles. PMID: 30628077
     
  7. Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, Everett PC, Truong MT. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: A National Cancer Database analysis. Head Neck. 2018 06; 40(6):1174-1184.View Related Profiles. PMID: 29417687
     
  8. Tan JN, Kroll MH, O'Hara CJ, Everett PC, Erdogan E. Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement. Clin Chim Acta. 2012 Oct 9; 413(19-20):1696-9.View Related Profiles. PMID: 22561184; DOI: 10.1016/j.cca.2012.04.020;
     
  9. Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One. 2010 Sep 02; 5(9). PMID: 20824065; PMCID: PMC2932743; DOI: 10.1371/journal.pone.0012520;
     
  10. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007 Jan; 82(1):23-30.View Related Profiles. PMID: 16947318
     
Showing 10 of 16 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 16 publications over 14 distinct years, with a maximum of 2 publications in 2000 and 2021

YearPublications
19991
20002
20021
20041
20051
20071
20101
20121
20181
20191
20201
20212
20221
20231

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cancer Metabolism
Esophageal Cancers
Lung Cancers
Nutritional Interventions in Cancer
Squamous Carcinomas of the Head and Neck
Contact for Mentoring:

830 Harrison Ave
Boston MA 02118
Google Map

617.638.6428
Download vCard

Everett's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (121) concept(s)
_
Co-Authors
See all (9) people
_
Similar People
See all (60) people
_
Same Department
Search Department